Stock comparison
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALGN
Align Technology
Market cap
$11.68B
Sector
Healthcare
RMD
ResMed
Market cap
$30.31B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
| Strategy | ALGN | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 56C | 72B | RMD |
| Benjamin Graham | 66B | 75B | RMD |
| Philip Fisher | 40D | 75B | RMD |
| Peter Lynch | 18F | 58C | RMD |
| Joel Greenblatt | 36D | 47D | RMD |
| Charlie Munger | 42D | 69B | RMD |
| Terry Smith | 44D | 73B | RMD |
| Metric | ALGN | RMD |
|---|---|---|
| Market cap | $11.68B | $30.31B |
| P/E (TTM) | 26.1x | 19.6x |
| EV/EBIT | 16.7x | 17.1x |
| ROIC (TTM) | 9.72% | 19.63% |
| Gross margin | 67.68% | 61.69% |
| Net margin | 10.5% | 27.44% |
| Revenue CAGR 5y | 0.52% | 12.64% |
| EPS CAGR 5y | -12.78% | 30.73% |
| Debt / Equity | 0.0x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALGN leads on
RMD leads on
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.